Immatics N.V. (IMTX) News
NASDAQ: IMTXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
5.77-0.18 (-3.03%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
IMTX news summary
We found 6 recent headlines mentioning Immatics N.V. (IMTX): 0 in the past week and 3 in the past 30 days, most often from Nasdaq, GlobeNewswire. For price context, IMTX is down 3.03% at $5.77. The most recent story, "Immatics Announces Third Quarter 2026 Financial Results and Business Update", was published by GlobeNewswire on Nov 10, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Immatics N.V. headlines
- Immatics Announces Third Quarter 2026 Financial Results and Business UpdateHouston, Texas and Tuebingen, Germany, November 10, 2026 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), the global leader in precision targeting of PRAME with multiple clinical-stage…GlobeNewswire
- Bristol Myers Squibb (BMY) Q3 Earnings and Revenues Beat EstimatesBristol Myers (BMY) delivered earnings and revenue surprises of +11.57% and +4.07%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?NasdaqBMY, IMTX
- Immatics Presents Clinical Activity of IMA402 PRAME Bispecific and IMA203CD8 PRAME Cell Therapy across Advanced Solid Tumors in Two Oral Presentations at 2026 ESMO Annual MeetingHouston, Texas and Tuebingen, Germany, October 24, 2026 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), the global leader in precision targeting of PRAME with multiple clinical-stage…GlobeNewswire
- Immatics N.V. Announces Updated Phase 1 Data for IMA203CD8 with 51% Objective Response RateImmatics N.V. announced updated Phase 1 data for its IMA203CD8 PRAME TCR T-cell therapy across multiple solid tumor types. As of the August 7, 2026 data cutoff, 98 heavily pretreated patients across…NasdaqIMTX, BF.A
- Stifel Initiates Coverage of Immatics N.V. at BuyFintel reports that on October 14, 2026, Stifel initiated coverage of Immatics N.V. (NASDAQCM:IMTX) (DB:4A3) with a Buy recommendation.Immatics N.V., based in Germany, operates in the biotechnology…Nasdaq
- Madrigal Q1 Earnings Beat, MASH Drug Sales Drive Top Line, Stock UpMDGL stock up on better-than-expected first-quarter results on account of robust Rezdiffra sales, driven by strong MASH demand and rising patient adoption.NasdaqINO, MDGL, IMTX